SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Knight Therapeutics Inc. (KHTRF) , forward earnings yield 3.10%. PEG 1.40.
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
- Forward P/E 32.3
- PEG Ratio 1.40 — between 1.0–2.0 indicates moderate valuation relative to growth.
Overall SharesGrow Score: 46/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — KHTRF
Valuation Multiples
P/E (TTM)0.0
Forward P/E32.3
PEG Ratio1.40
Forward PEG1.40
P/B Ratio0.00
P/S Ratio1.22
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.05
Forward EPS (Est.)$0.17
Book Value / Share$0.00
Revenue / Share$4.52
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield3.10%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.15 |
$5.94M |
$18.56M |
312.5% |
| 2017 |
$0.12 |
$8.63M |
$17.24M |
199.7% |
| 2018 |
$0.17 |
$12.5M |
$24.08M |
192.6% |
| 2019 |
$0.10 |
$47.46M |
$14.52M |
30.6% |
| 2020 |
$0.24 |
$199.52M |
$31.76M |
15.9% |
| 2021 |
$0.13 |
$243.48M |
$15.68M |
6.4% |
| 2022 |
$-0.26 |
$293.56M |
$-29.89M |
-10.2% |
| 2023 |
$-0.16 |
$328.2M |
$-16.84M |
-5.1% |
| 2024 |
$0.04 |
$371.3M |
$4.33M |
1.2% |
| 2025 |
$-0.05 |
$449.72M |
$-5.37M |
-1.2% |
